Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $414.22, for a total value of $1,242,660.00. Following the completion of the transaction, the insider directly owned 106,914 shares in the company, valued at $44,285,917.08. This trade represents a 2.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Solomon Moshkevich also recently made the following trade(s):
- On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The shares were sold at an average price of $326.89, for a total value of $4,955,652.40.
- On Tuesday, September 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $320.73, for a total transaction of $962,190.00.
- On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80.
- On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The shares were sold at an average price of $254.07, for a total transaction of $305,900.28.
- On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The stock was sold at an average price of $260.49, for a total transaction of $263,094.90.
Natera Trading Up 0.5%
Shares of NTRA stock traded up $1.88 during mid-day trading on Friday, reaching $410.35. The stock had a trading volume of 2,156,324 shares, compared to its average volume of 1,566,597. The stock’s 50-day moving average price is $332.39 and its two-hundred day moving average price is $261.01. Natera, Inc. has a 52-week low of $160.59 and a 52-week high of $427.47. The firm has a market capitalization of $59.15 billion, a PE ratio of -301.73 and a beta of 1.50.
Wall Street Analysts Forecast Growth
NTRA has been the topic of a number of research analyst reports. The Goldman Sachs Group assumed coverage on shares of Natera in a research report on Friday, June 5th. They set a “neutral” rating and a $245.00 price objective on the stock. Citigroup lifted their target price on shares of Natera from $315.00 to $365.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Canaccord Genuity Group set a $375.00 price target on shares of Natera in a research report on Friday, August 7th. Wells Fargo & Company increased their price target on shares of Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Finally, UBS Group raised their price objective on shares of Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $341.55.
Check Out Our Latest Report on NTRA
Hedge Funds Weigh In On Natera
Several large investors have recently modified their holdings of NTRA. BlackRock Inc. bought a new position in Natera during the 2nd quarter valued at about $2,962,770,000. JPMorgan Chase & Co. grew its stake in shares of Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares during the period. Bank of America Corp DE purchased a new position in shares of Natera during the second quarter valued at approximately $199,960,000. Arrowstreet Capital Limited Partnership raised its holdings in shares of Natera by 111.1% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,179,939 shares of the medical research company’s stock valued at $270,312,000 after purchasing an additional 620,954 shares during the last quarter. Finally, Legal & General Group Plc bought a new position in Natera during the second quarter valued at approximately $150,143,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.
Natera Company Profile
Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.
Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders.
See Also
- Five stocks we like better than Natera
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
